Observation period and defined risk periods for an individual person receiving oral glucocorticoid treatment who stops treatment before end of follow up.</p
Risk of adverse drug reactions by time period from the start of raltegravir treatment.</p
Cumulative incidence of premature treatment termination and readmission by group.</p
<p>Use of sun protection measures according to time elapsed from diagnosis (patients' group only).</...
Incidence of adverse events during on-treatment follow-up and whole study period.</p
<p>Timing of treatment intensification after risk factor test (number of patients per 10 days period...
<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocor...
<p>Predicted and observed risk of viral control according to the longer interval of treatment discon...
<p>Interrupted time series analyses results, reporting immediate changes in treatment of cardiovascu...
<p>Timing of response to treatment evaluation after treatment intensification (number of patients pe...
<p>Survival models results for risk factors associated with treatment interruption.</p
<p>The changes in the HbA1c values and other medical conditions in the observation period.</p
<p>Self-controlled case series (SCCS) model with observation period, baseline period and risk period...
Characteristics of 286,680 oral glucocorticoid users according to sex, age, glucocorticoid type, dos...
<p>Demographic and clinical data for all subjects by disease status classification (extension study ...
<p>The incidence of subsequent short-term and long-term morbidity stratified by follow-up period.</p
Risk of adverse drug reactions by time period from the start of raltegravir treatment.</p
Cumulative incidence of premature treatment termination and readmission by group.</p
<p>Use of sun protection measures according to time elapsed from diagnosis (patients' group only).</...
Incidence of adverse events during on-treatment follow-up and whole study period.</p
<p>Timing of treatment intensification after risk factor test (number of patients per 10 days period...
<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocor...
<p>Predicted and observed risk of viral control according to the longer interval of treatment discon...
<p>Interrupted time series analyses results, reporting immediate changes in treatment of cardiovascu...
<p>Timing of response to treatment evaluation after treatment intensification (number of patients pe...
<p>Survival models results for risk factors associated with treatment interruption.</p
<p>The changes in the HbA1c values and other medical conditions in the observation period.</p
<p>Self-controlled case series (SCCS) model with observation period, baseline period and risk period...
Characteristics of 286,680 oral glucocorticoid users according to sex, age, glucocorticoid type, dos...
<p>Demographic and clinical data for all subjects by disease status classification (extension study ...
<p>The incidence of subsequent short-term and long-term morbidity stratified by follow-up period.</p
Risk of adverse drug reactions by time period from the start of raltegravir treatment.</p
Cumulative incidence of premature treatment termination and readmission by group.</p
<p>Use of sun protection measures according to time elapsed from diagnosis (patients' group only).</...